Search Results

Propanc Biopharma, Inc. today announced that a Certificate of Grant for the Company’s “proenzymes composition” patent was received from the Japanese Patent Office.

Propanc Biopharma, Inc. today announced that a certificate of grant for the Company’s “composition of proenzymes for cancer treatment,” patent was received from the European Patent Office.

Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.

Propanc Biopharma, Inc. today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.

Propanc Biopharma, Inc. today announced that the Company’s joint researcher, Mrs. Belén Toledo Cutillas, has commenced an internship at the Cancer Center Amsterdam – vUMC (University Medical Centers).

Propanc Biopharma, Inc. announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors.

Propanc Biopharma, Inc. announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy.

Propanc Biopharma, Inc. today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.

Propanc Biopharma, Inc. announced that a peer reviewed scientific article published by the Company and its research partners reached 3,000 reads on July 6, 2023, according to ResearchGate.

Propanc Biopharma, Inc. today announced that the Company will target the Peter Mac Cancer Center in Melbourne, Australia, as the site for the First-In-Human (FIH) study for PRP in patients with advanced solid tumors.